Tag: biorxiv neuroscience

  • bioRxiv Microbiology: 2026 Subject Growth

    bioRxiv’s microbiology collection holds more than 41,000 preprints as of July 2026, making it the platform’s third-largest subject area behind neuroscience (over 90,000) and bioinformatics (nearly 43,000). Together, these three fields account for close to two-fifths of every preprint ever posted to bioRxiv since its 2013 launch — a concentration that says as much about where biology’s fastest-moving fields are as it does about the platform itself.

    bioRxiv is a free, non-profit preprint repository for the biological sciences, now operated by openRxiv, on which authors post manuscripts before or independent of journal peer review, sorted into 27 subject-specific collections spanning everything from paleontology to synthetic biology.

    What is bioRxiv, and how are preprints organised by subject?

    bioRxiv was co-founded by John Inglis and Richard Sever in November 2013 as an open-access preprint repository hosted by Cold Spring Harbor Laboratory. In March 2025, bioRxiv and its clinical-sciences counterpart medRxiv transferred to openRxiv, a newly formed non-profit created specifically to steward both platforms, as reported by Science.

    Every submission is placed into one of 27 subject collections at the point of posting. There is no fee to submit to bioRxiv, and authors self-select the collection that best matches their manuscript. This subject taxonomy is what makes volume comparisons across fields possible — and what this analysis draws on directly.

    One structural exception worth noting: the Epidemiology collection is now closed to new submissions following the completion of bioRxiv’s clinical-research pilot project, meaning its growth curve has effectively flattened while other collections continue to expand.

    How does bioRxiv microbiology compare to neuroscience and other subjects by volume?

    Based on a live count of bioRxiv’s own subject-collection pages taken on 3 July 2026, neuroscience is the platform’s largest single collection at 90,290 preprints — a 19.4% share of the roughly 465,700 preprints posted across all 27 collections to date. Bioinformatics follows at 42,825 (9.2%), with microbiology close behind at 41,133 (8.8%).

    Cell biology, evolutionary biology, genomics and biophysics round out the next tier, each holding between roughly 21,000 and 26,000 preprints. At the other end of the scale, paleontology (678) and clinical trials (138) remain niche collections by comparison, while epidemiology’s 2,067 total is now largely fixed given its closure to new submissions.

    Full ranking of bioRxiv’s largest subject collections

    Rank Subject collection Cumulative preprints Share of total
    1 Neuroscience 90,290 19.4%
    2 Bioinformatics 42,825 9.2%
    3 Microbiology 41,133 8.8%
    4 Cell Biology 25,753 5.5%
    5 Evolutionary Biology 24,737 5.3%
    6 Genomics 22,868 4.9%
    7 Biophysics 21,837 4.7%
    8 Ecology 20,284 4.4%
    9 Cancer Biology 18,775 4.0%
    10 Biochemistry 18,098 3.9%

    Source: CASRAI analysis of live bioRxiv subject-collection article counts, recorded 3 July 2026. These are cumulative totals since bioRxiv’s 2013 launch, not annual submission rates, so they reflect sustained field-level adoption of preprinting rather than a single year’s activity.

    Microbiology’s position just behind bioinformatics is notable given how differently the two fields work: bioinformatics preprints are often fast, computational and low-cost to produce, while microbiology preprints typically follow wet-lab experimental cycles. That microbiology has nonetheless built a corpus within a few thousand papers of bioinformatics points to strong, sustained preprinting culture within microbiology specifically — likely reinforced by the field’s pandemic-era experience with rapid-dissemination norms.

    Why does subject-level concentration matter for research administrators?

    For institutional leaders and research-administration teams, subject-level preprint concentration is a proxy for where scholarly communication norms are shifting fastest. A field with tens of thousands of preprints has, in effect, normalised pre-peer-review dissemination as a routine step in its publication workflow — with direct implications for how institutions track outputs, credit early dissemination in tenure and promotion review, and advise researchers on preprint policy.

    • Grant and promotion committees increasingly need clear policy on whether preprints count as citable outputs, particularly in high-volume fields like neuroscience and microbiology.
    • Research offices supporting microbiology, bioinformatics or genomics groups should expect preprint-first workflows to already be the norm, not the exception, among active researchers.
    • Fields with low preprint volume (pathology, zoology, clinical trials) may need different guidance, since preprinting culture there remains comparatively immature.

    This is also a live concern for research administrators and institutional leaders tracking how open-research norms diffuse unevenly across disciplines — subject-level data of this kind gives institutions a concrete basis for that assessment, rather than relying on anecdote.

    Common questions about bioRxiv preprints

    Is bioRxiv a preprint server?

    Yes. bioRxiv is a dedicated preprint server for the biological sciences, distributing manuscripts before or alongside formal peer review. It is operated by openRxiv, a non-profit created in 2025 specifically to run bioRxiv and medRxiv, and hosts subject collections spanning microbiology, neuroscience, genomics and 24 other biology-related fields.

    Can anyone submit to bioRxiv?

    Authors can deposit a manuscript in draft or final form provided it concerns a relevant scientific field, is unpublished at the time of submission, and all co-authors have consented. Authors must first register on the platform. bioRxiv screens submissions for basic scope and ethical compliance before posting, but does not conduct peer review.

    How much does it cost to publish in bioRxiv?

    There is no fee to submit a preprint to bioRxiv. This free-to-post model is a key driver of its growth across every subject collection, including the microbiology and neuroscience volumes analysed above, since it removes the cost barrier that applies to many open-access journal publication routes.

    Does bioRxiv count as published?

    A bioRxiv preprint is not equivalent to a peer-reviewed publication. It establishes a timestamped, citable public record of the work, and many journals allow later submission of the same manuscript, but it has not undergone formal peer review at the point of posting. Institutions and funders vary in how they weight preprints in assessment.

    Implications and outlook for scholarly communication

    The concentration of preprint volume in neuroscience, bioinformatics and microbiology is likely to persist rather than reverse. These fields combine large, active researcher populations with production cycles well suited to rapid dissemination, and none shows structural barriers comparable to epidemiology’s now-closed pilot pathway.

    For research-administration teams, the practical takeaway is to treat preprint-volume data by subject as a planning input: policy on preprint citation, researcher guidance, and repository integration should be calibrated to each discipline’s actual adoption level rather than applied uniformly across an institution’s full research portfolio.

  • bioRxiv or medRxiv? Choosing the Right Server for Clinical vs Basic Research

    bioRxiv or medRxiv? Choose bioRxiv for basic, non-clinical life-sciences research such as genetics, microbiology or neuroscience, and medRxiv for clinical, epidemiological or public-health research that could influence patient care. The two preprint servers do not overlap: posting the same manuscript to both is prohibited and can result in withdrawal.

    A preprint server is an open-access repository where researchers post a scientific manuscript publicly before it has completed formal peer review. bioRxiv and medRxiv are the two sibling servers operated by openRxiv for the life and health sciences respectively, and the correct choice between them depends on subject scope, not on which sounds more prestigious.

    On this page:

    What is the difference between bioRxiv and medRxiv?

    bioRxiv launched in 2013 at Cold Spring Harbor Laboratory (CSHL) as a preprint server for basic biology; medRxiv followed in 2019 as a dedicated server for clinical and health-sciences manuscripts. In March 2025, CSHL transferred governance of both platforms to openRxiv, a newly formed independent nonprofit, marking the most significant structural change since bioRxiv’s founding.

    Neither server is a journal. medRxiv is not a journal — it is a repository, and nothing posted there has been peer reviewed or certified. Both platforms carry explicit caution notices stating that preprints should not guide clinical practice, inform health-related behaviour, or be reported as established findings.

    The practical distinction authors need is scope, not scale: bioRxiv covers fundamental biological research with new data, while medRxiv is reserved for work that could plausibly influence a clinical decision, a public-health response, or patient behaviour.

    Where should clinical trials and health research go?

    Any manuscript reporting a clinical trial, an epidemiological study, or research with direct implications for diagnosis, treatment or public-health policy belongs on medRxiv. bioRxiv’s own submission guidance is explicit that new clinical trial reports and most epidemiology submissions must now go to medRxiv rather than bioRxiv.

    medRxiv applies stricter screening than bioRxiv precisely because misinterpreted clinical claims carry public-harm risk. One detail authors frequently miss: medRxiv does not accept case reports or case series, so single-patient or small-series clinical write-ups need a different outlet even when the subject matter is unambiguously medical.

    • Randomised controlled trials and other interventional studies
    • Epidemiological and public-health surveillance research
    • Studies involving patient-level clinical or health-behaviour data
    • Infectious disease, oncology, cardiovascular medicine and psychiatry manuscripts

    Where should microbiology, neuroscience and basic biology go?

    bioRxiv is the correct venue when the research advances fundamental biological understanding without a direct clinical application. Its subject categories include microbiology, neuroscience, genetics, immunology, cell biology and bioinformatics, among others, and submissions are screened by volunteer bioRxiv Affiliates chiefly for scope, plagiarism and public-harm potential.

    A microbiology paper characterising a novel bacteriophage, or a neuroscience paper mapping neural circuitry in a model organism, sits comfortably on bioRxiv provided it does not extend into patient data or treatment recommendations. The moment a microbiology study becomes an infectious-disease outbreak analysis, or a neuroscience study becomes a neurology or psychiatry treatment study, the correct server changes to medRxiv.

    How do you decide when a study sits on the border?

    Most submission confusion happens in a handful of predictable grey zones where a basic-science category on bioRxiv has a clinical counterpart on medRxiv. openRxiv’s own subject-category lists make the pairing explicit, and mapping them side by side is the fastest way to resolve a borderline decision.

    bioRxiv category (basic science) medRxiv category (clinical counterpart) Decision rule
    Genetics / Genomics Genetic and Genomic Medicine Patient-directed diagnosis or therapy → medRxiv
    Neuroscience Neurology / Psychiatry and Clinical Psychology Patient treatment or behaviour outcomes → medRxiv
    Microbiology Infectious Diseases Outbreak, surveillance or patient-cohort data → medRxiv
    Pharmacology and Toxicology Pharmacology and Therapeutics Human dosing, trial or therapeutic outcome data → medRxiv

    As a working test: if the manuscript’s conclusion could reasonably change what a clinician does at the bedside, or what a public-health body recommends, it belongs on medRxiv regardless of how “basic” the underlying technique feels. If it reports mechanism, model-organism data or method development with no direct patient or population-health claim, bioRxiv is the right home.

    Under the International Committee of Medical Journal Editors’ recommendations, posting to a recognised preprint server does not count as prior or duplicate publication and does not preclude subsequent journal submission — but authors should still confirm the target journal’s own preprint policy before posting either version.

    Questions authors ask

    Is bioRxiv reputable?

    Yes. bioRxiv is a well-established, widely used life-sciences preprint server operated by openRxiv, screened by volunteer affiliates for plagiarism, scope and biosafety concerns. It is not peer reviewed, but it is recognised across academic biology as a legitimate venue for early-stage research dissemination.

    Is medRxiv trustworthy?

    medRxiv applies a stricter, additional screening layer beyond bioRxiv’s because of the public-harm risk in clinical and health content. Every posted manuscript carries a prominent caution notice stating it has not been certified by peer review and should not guide clinical practice, making its scope and limitations transparent to readers.

    What is the difference between bioRxiv and medRxiv?

    bioRxiv covers basic, non-clinical life sciences; medRxiv is reserved for clinical, epidemiological and health-sciences research with potential patient or public-health impact. Screening intensity, disclaimer wording and accepted article types differ accordingly, and a single manuscript cannot be posted to both servers simultaneously.

    What are the alternatives to bioRxiv?

    Depending on field, authors also use arXiv for quantitative and computational biology work, Research Square or journal-integrated “In Review” services, and discipline-specific repositories such as ChemRxiv. None of these substitute for medRxiv when a manuscript is clinically actionable.

    What this means for authors and institutions

    For individual authors, the server choice is a compliance decision, not a branding one: submitting a clinical manuscript to the wrong server risks a request to withdraw and resubmit, delaying the timestamp priority a preprint is meant to secure. Research administrators tracking institutional preprint activity — an increasingly routine part of research administration workflows — should build the bioRxiv/medRxiv scope test into pre-submission checklists rather than leaving it to individual author judgement.

    For institutions and publishers, the March 2025 move to independent openRxiv governance is worth tracking: it signals that preprint infrastructure for biology and medicine is now managed as permanent scholarly-communication infrastructure rather than a single laboratory’s side project, with implications for long-term archival stability and policy planning. Definitions of related terms, including preprint, postprint and version of record, are maintained in the CASRAI Research Administration Dictionary.

    The practical rule holds regardless of field: match the manuscript’s real-world consequence, not its disciplinary label, to the server’s scope, and treat the bioRxiv/medRxiv boundary as a public-harm question rather than a prestige one.